131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO, CA
Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update
Reports Second Quarter 2025 Financial Results and Provides Business Update
Provides Executive Leadership Update
Reports First Quarter 2025 Financial Results and Provides Business Update
Annual Report to Security Holders
Changes in Board, Management or Compensation
Costs of Shutting Down or Selling Parts of the Business
Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Q2
Q1
FY 2023
Q3
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Post-Effective Amendment to Registration Statement
Correspondence
Submission Upload
Definitive Revised Proxy Statement
S-1MEF